I don’t understand any issues with the new research framework. To me it is greatly superior focus , * “markedly so“ - and is pivoting trials focus to the most important.
It is great to see the results of many months of work and progress from this year .
(* to borrow a past John Cullity phrase - I love hearing him rolling words off his tongue He is remarkable imo )
Race Oncology employed top industry consultants and have a world leading cohort of consultant clinicians advising , lead by Prof Borje Andersson ; and very competent leadership also from Daniel , John , and now Phil .
As John referred to —RAC are in conversations with large Pharmaceutical companies .
The real intent is to go for the optimal direction and targeted use of efforts , & setting up trials and clinical work - to the very best , achievable , and most speedy way to scope bisantrene towards the real target of approvals pathways and partnering .
This plan is the result and at the behest of major potential partners .
How obvious is this ?
MRD will be implied in effect, with efficacy shown in AML .
Targeting the mechanism of potential action to which bisantrene has effectiveness (FTO protein) , and targeting mainstream large need serious major cancers linked to this - is excellent & a huge amount of consulting has to have gone into this .
Breast cancer clearly is most important to get underway in trials - the preclinical work is done, ++ Race have all of the historic trials data known & which is useable . The historical data , is already significant.
Bisantrene has now been shown as highly efficacious in pairing with the same drugs as commonly used with Doxyrubicin , against a spectrum of Breast cancers —this is obvious , the doxorubicin alternative trial has to be priority .
**We want bisantrene available to breast cancer sufferers.
None of the old is being lost with the new really . It isn’t even so much new as additional , to me— which we would expect with all that has come to light and the dynamic nature of oncology research and targeting of approach .
New methods and targets are important-
**FTO is a major new compelling reason ‘why’ bisantrene has such high efficacy , against a broad number of cancers , all with high mortalities .
Approvals for Bisantrene & even having it approved for experimental use in specific cancers - will open the door for applications for use to treat other dire cancers where past efficacy or trials data shows a high degree of likely efficacy.
- Forums
- ASX - By Stock
- RAC
- Ann: Change in substantial holding
Ann: Change in substantial holding, page-51
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.89 |
Change
-0.050(2.58%) |
Mkt cap ! $313.4M |
Open | High | Low | Value | Volume |
$1.95 | $1.95 | $1.84 | $640.4K | 340.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5685 | $1.88 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.89 | 1588 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5685 | 1.875 |
1 | 3300 | 1.870 |
5 | 47471 | 1.840 |
1 | 835 | 1.835 |
3 | 7400 | 1.830 |
Price($) | Vol. | No. |
---|---|---|
1.890 | 1588 | 1 |
1.900 | 234 | 1 |
1.910 | 235 | 1 |
1.945 | 5405 | 1 |
1.950 | 7570 | 1 |
Last trade - 15.26pm 15/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online